Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies

2 Apr 2019

Abstract excerpt

Acute myeloid leukemia (AML) is a devastating disease, with the majority of patients dying within a year of diagnosis. For patients with relapsed/refractory AML, the prognosis is particularly poor with currently available treatments. Although genetically heterogeneous, AML subtypes share a common differentiation arrest at hematopoietic progenitor stages. Overcoming this differentiation arrest has the potential to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Biochemical and Molecular Research
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30940908
DOI: 10.1038/s41375-019-0461-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesPMID 30940908Read ↗

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid LeukemiaSemantic proximity Read ↗

The Synergism Between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid LeukemiaSemantic proximity Read ↗

Differentiation therapy of myeloid leukemia: four decades of developmentSemantic proximity Read ↗

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Recent Developments in Differentiation Therapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

Recent Developments in Differentiation Therapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

Differentiation therapy for myeloid malignancies: beyond cytotoxicity.Semantic proximity Read ↗

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.Semantic proximity Read ↗

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemiaSemantic proximity Read ↗

Differentiation therapy of acute myeloid leukemia: past, present and futureSemantic proximity Read ↗

Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase MutationsSemantic proximity Read ↗

BCOR Mutations Define a Therapeutic Vulnerability to DHODH Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.